查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715480

胚胎著床前基因檢測市場（按檢測交付類型、檢測類型、技術類型、產品和最終用戶分類）—2025-2030 年全球預測

Preimplantation Genetic Testing Market by Testing Type, Test Type, Technology Type, Offering, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 2024 年胚胎著床前基因檢測市值將達到 7.8019 億美元，到 2025 年將以 12.23% 的複合年成長率成長至 8.7374 億美元，到 2030 年將達到 15.5987 億美元。

主要市場統計數據
基準年2024年 7.8019億美元
預計年份：2025年 8.7374億美元
預測年份 2030 15.5987億美元
複合年成長率（%） 12.23%

胚胎著床前基因檢測（PGT）已成為生殖醫學變革的支柱，為人類發展的早期階段帶來了希望和清晰的認知。如今，基因篩檢和診斷技術的進步使得在胚胎著床前識別潛在的基因異常成為可能，從而降低遺傳疾病的風險並確保更健康的結果。在個人化醫療和針對性診斷需求日益成長的時代，這一發展尤其重要。

PGT技術的演變受到臨床研究數量的增加、檢測技術的改進以及生物技術公司和醫療中心之間合作的加強的推動。隨著生育診所和診斷實驗室採用尖端的基因篩檢工具，技術創新提高了可近性和效率，情況正在迅速改變。在這種動態環境中，鼓勵相關人員探索強大的基因檢測通訊協定，並採用利用親代和胚胎遺傳學最新見解的綜合策略。

因此，市場呈現上升趨勢，加強了研究舉措，並使得生殖保健方法更加全面。每項技術突破都有望提高生育治療的安全性和成功率，使臨床醫生和患者都能更輕鬆地完成治療。

改變胚胎著床前基因檢測市場

近年來，發生了一系列變革，重新定義了胚胎著床前基因檢測市場的輪廓。該行業採用了尖端技術和方法，大大提高了基因篩檢的準確性和可靠性。這個領域歷來依賴標準細胞遺傳學方法，現在正採用高解析度基因組工具，導致診斷準確性和吞吐量的模式轉移。

最顯著的進步之一是次世代定序儀的整合。該技術不僅提高了對輕微染色體異常的檢測能力，而且還能夠以無與倫比的精度同時檢測多種遺傳疾病。此外，從傳統的聚合酵素鏈鎖反應（PCR）的測試到更複雜的基因組雜合反應技術的演變，創造了增強臨床信心的環境。

全球法律規範也不斷發展以適應這些進步。新的指南越來越認知到基因組完整性的重要性以及全面、高保真胚胎著床前測試的必要性。此外，公共研究機構和私人公司之間加強合作正在為整個行業創造協同效應並刺激進一步的創新。由於這種模式轉移，市場正在走向更有效、個人化治療方法和改善患者治療效果的時代。

胚胎著床前基因檢測市場的關鍵細分洞察

仔細觀察市場區隔就會發現一個微妙的圖景，反映出多樣化的檢測技術、先進的技術和多樣化的最終用途。按測試類型細分，檢視 PGT-A（涵蓋非整倍體監測）、PGT-M（專注於檢測單基因疾病）和 PGT-SR（旨在分析結構重排）的市場。由於有效診斷所需的特異性和準確性，每個類別都呈現出獨特的挑戰和機會。

此外，按檢測類型分類，可分為胚胎著床前基因診斷和胚胎著床前基因篩檢，前者主要用於檢測高風險夫婦中已知的基因或染色體異常，後者對胚胎中潛在的基因異常進行更廣泛的調查。這兩種方法可以有效地篩檢多種遺傳疾病，並根據不同患者的需求提供量身定做的解決方案。

在技​​術領域，市場細分涵蓋一系列技術，從比較基因組雜合反應和螢光原位雜合技術到下一代定序、基於 PCR 的測試和單核苷酸多態性分析。這些方法的進步顯著提高了基因檢測方法的準確性、可擴展性和可負擔性。對先進技術的依賴程度不斷提高不僅提高了診斷的準確性，也為進一步的科學創新鋪平了道路。

另一個重要方面是按產品細分，透過儀器、試劑、消耗品和專用軟體的視角來審視市場。這些組件構成了檢查過程的支柱，每個環節的進步都凸顯了自動化和資料分析的主要趨勢。

最後，從最終用戶的觀點來看，市場已經涵蓋診斷實驗室、生育診所、醫院和研究機構。隨著不同營業單位擴大尋求臨床效率和技術複雜性之間的平衡，這種細分加強了 PGT 技術的廣泛應用。了解這種多方面的細分模型將有助於相關人員了解市場趨勢、策略性地分配資源並推動生殖保健這一關鍵領域的進一步創新。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 改善醫療保健基礎設施並增加世界各地基因檢測設施的使用機會
      • 體外受精 (IVF) 程序和胚胎著床前基因檢測的需求增加
      • 提高準父母對遺傳疾病及其預防的認知
    • 限制因素
      • 胚胎著床前基因檢測程序的高成本限制了其廣泛普及和採用
    • 機會
      • 技術進步提高了胚胎著床前基因檢測的準確性和速度
      • 與 IVF 診所合作提供配套服務
    • 任務
      • 遵守各種當地法規和道德標準
  • 市場區隔分析
    • 檢測類型：PGT-M 預防遺傳疾病傳播的需求日益增加
    • 最終用戶：生育診所擴大使用胚胎著床前基因檢測來提高 IVF 成功率
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章胚胎著床前基因檢測市場（依檢測類型分類）

  • 介紹
  • PGT-A（非整倍體）
  • PGT-M（單基因疾病）
  • PGT-SR（結構重組）

第7章胚胎著床前基因檢測市場（依檢測類型）

  • 介紹
  • 胚胎著床前基因診斷
  • 胚胎胚胎著床前基因篩檢

第8章胚胎著床前基因檢測市場（依技術類型）

  • 介紹
  • 比較基因組雜合反應
  • 螢光原位雜合技術
  • 下一代定序
  • PCR檢測
  • 單核苷酸多態性

第9章胚胎著床前基因檢測市場（依產品提供）

  • 介紹
  • 裝置
  • 試劑和耗材
  • 軟體

第 10 章 胚胎胚胎著床前基因檢測市場（依最終用戶分類）

  • 介紹
  • 診斷實驗室
  • 不孕不育診所
  • 醫院
  • 研究所

第 11 章美洲胚胎著床前基因檢測市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太地區胚胎胚胎著床前基因檢測市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲胚胎著床前基因檢測市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Techne Corporation
  • Bioarray SL
  • EUROPE IVF International sro
  • F. Hoffmann-La Roche AG
  • Genea Limited
  • GENETiKS
  • Illumina, Inc.
  • Invicta Genetics
  • Invitae Corporation
  • Juno Genetics, US Inc.
  • Laboratory Corporation of America Holdings
  • MedGenome Labs Ltd.
  • Merck KGaA
  • Natera, Inc.
  • NextGen Genetics Holdings, LLC
  • Ovation Fertility
  • PacGenomics
  • PerkinElmer, Inc.
  • Progyny, Inc.
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Reproductive Genetic Innovations, LLC
  • SEQUENCE46, LLC
  • Sysmex Corporation
  • Takara Bio Inc.
  • The Cooper Companies Inc.
  • Thermo Fisher Scientific Inc.
  • Vitrolife Sweden AB
  • Yikon Genomics（Shanghai）Co., Ltd.
Product Code: MRR-030EE48515DA

The Preimplantation Genetic Testing Market was valued at USD 780.19 million in 2024 and is projected to grow to USD 873.74 million in 2025, with a CAGR of 12.23%, reaching USD 1,559.87 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 780.19 million
Estimated Year [2025] USD 873.74 million
Forecast Year [2030] USD 1,559.87 million
CAGR (%) 12.23%

Preimplantation Genetic Testing (PGT) has emerged as a transformative pillar in reproductive medicine, offering hope and clarity at the earliest stages of human development. Advances in genetic screening and diagnostic techniques have made it possible to identify potential genetic anomalies before implantation, thereby mitigating the risk of inherited disorders and ensuring healthier outcomes. This development is particularly significant in an era where the demand for personalized medicine and targeted diagnostics is intensifying.

The evolution in PGT technologies is driven by an ever-growing body of clinical research, improvements in laboratory techniques, and increased collaboration among biotechnology firms and healthcare institutions. As both fertility clinics and diagnostic laboratories incorporate state-of-the-art genetic screening tools, the landscape is evolving rapidly, with innovation leading to greater accessibility and efficiency. In this dynamic environment, stakeholders are encouraged to explore robust genetic testing protocols and adopt integrative strategies that leverage the latest insights in parental and embryonic genetics.

The market has thus witnessed an upward trajectory, bolstering research initiatives and enabling a more comprehensive approach to reproductive health. With each technological breakthrough, the promise of improved safety and higher success rates in fertility treatments becomes increasingly attainable for clinicians and patients alike.

Transformative Shifts in the Preimplantation Genetic Testing Landscape

Recent years have seen a series of transformative shifts that have redefined the contours of the preimplantation genetic testing market. The industry has embraced cutting-edge technologies and methodologies that have significantly improved the precision and reliability of genetic screenings. Historically reliant on standard cytogenetic techniques, the field has now incorporated high-resolution genomic tools, leading to a paradigm shift in diagnostic accuracy and throughput.

One of the most notable advancements has been the integration of next-generation sequencing. This technology not only enhances the detection of minor chromosomal aberrations but also enables simultaneous testing for multiple genetic conditions with unmatched precision. Additionally, the evolution from traditional polymerase chain reaction (PCR)-based testing to more sophisticated genomic hybridization techniques has fostered an environment of enhanced clinical reliability.

Regulatory frameworks on a global scale are also shifting to accommodate these advancements. Newer guidelines are increasingly acknowledging the importance of genomic integrity and the necessity for comprehensive, high-fidelity preimplantation testing. Furthermore, improved collaboration between public research institutions and private enterprises has led to industry-wide synergy, spurring further innovation. The resulting paradigm shifts have, therefore, propelled the market towards an era of higher efficacy, tailored treatment modalities, and improved patient outcomes.

Key Segmentation Insights of the Preimplantation Genetic Testing Market

An in-depth examination of market segmentation reveals a nuanced landscape reflective of diverse testing techniques, advanced technologies, and varied end-use applications. The segmentation based on testing type examines the market across PGT-A, which targets aneuploidy investigation, PGT-M focused on monogenic disorder detection, and PGT-SR, designed to analyze structural rearrangements. Each category illustrates unique challenges and opportunities, driven by the specificity and accuracy required for effective diagnosis.

Furthermore, the division based on test type differentiates between preimplantation genetic diagnosis, primarily employed for detecting known genetic or chromosomal anomalies in high-risk couples, and preimplantation genetic screening, which provides a broader survey of potential genetic irregularities in embryos. This dual approach ensures that a wide range of genetic conditions can be effectively screened, offering tailored solutions for diverse patient needs.

In the realm of technology, the market segmentation covers an array of methodologies, from comparative genomic hybridization and fluorescent in-situ hybridization to next-generation sequencing, PCR-based testing, and single-nucleotide polymorphism analysis. Advancements in these methods have significantly elevated the precision, scalability, and affordability of genetic testing procedures. The growing reliance on high-throughput technologies has not only enhanced diagnostic accuracy but has also paved the way for further scientific innovations.

Another critical aspect is the segmentation based on offerings, which scrutinizes the market through the lens of instruments, reagents and consumables, and specialized software. These components form the backbone of the testing process, and advancements in each segment underscore the progressive trends in automation and data analytics.

Finally, when considering the end-user perspective, the market is studied across diagnostic laboratories, fertility clinics, hospitals, and research institutes. This segmentation reinforces the wide adoption of PGT technologies, as diverse entities increasingly seek to balance clinical efficiency with technological sophistication. By understanding these multifaceted segmentation models, stakeholders can ascertain market trends, allocate resources strategically, and drive further innovation within this critical area of reproductive medicine.

Based on Testing Type, market is studied across PGT-A (Aneuploidy), PGT-M (Monogenic Disorders), and PGT-SR (Structural Rearrangements).

Based on Test Type, market is studied across Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening.

Based on Technology Type, market is studied across Comparative Genomic Hybridization, Fluorescent In-Situ Hybridization, Next-Generation Sequencing, PCR-Based Testing, and Single-Nucleotide Polymorphism.

Based on Offering, market is studied across Instruments, Reagents & Consumables, and Software.

Based on End User, market is studied across Diagnostic Laboratories, Fertility Clinics, Hospitals, and Research Institutes.

Key Regional Insights of the Global Preimplantation Genetic Testing Market

The regional dynamics of the preimplantation genetic testing market reveal a rich tapestry of growth patterns, regulatory environments, and technological adoption across various geographical areas. In the Americas, a combination of robust healthcare infrastructure, significant investments in biotechnology, and progressive public health policies has resulted in rapid market expansion. The region represents a hub of clinical excellence and technological adoption, making it one of the most dynamic players in the global scenario.

Across Europe, the Middle East, and Africa, the market is characterized by a balanced mix of established healthcare systems and emerging markets. Here, stringent regulatory standards coupled with a surge in demand for precision diagnostics drive advancements and innovation. This area, while facing varied challenges, also presents significant opportunities through public-private partnerships and enhanced cross-border collaborations, which act as catalysts for market growth.

In the Asia-Pacific region, rapid urbanization, increasing awareness about reproductive health, and soaring investments in healthcare technologies have contributed to a vibrant market landscape. The convergence of technological know-how and increased demand for elite medical services has made this region a fertile ground for the adoption of preimplantation genetic testing. As healthcare systems in these regions continue to evolve, the market is anticipated to benefit from an influx of new players and innovative diagnostic solutions, further reinforcing its potential on the global stage.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Shaping the Preimplantation Genetic Testing Market

The competitive landscape in the preimplantation genetic testing market is marked by a diverse array of global players, each contributing to the rapid evolution of diagnostic technologies and clinical methodologies. Companies such as Abbott Laboratories and Agilent Technologies, Inc. have been front-runners, leveraging extensive research and innovation to deliver advanced genetic testing solutions. Their efforts are complemented by the expertise of organizations like Bio-Techne Corporation and Bioarray S.L., who continue to push the envelope in assay development and genomic analytics.

Emerging as significant competitors, enterprises such as EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, and Genea Limited have established a formidable presence in the sector through integrated platforms that combine clinical diagnostics with next-generation sequencing. GENETiKS, Illumina, Inc., and Invicta Genetics have further revolutionized the market by streamlining data analysis and enhancing the precision of genetic screenings.

Invitae Corporation and Juno Genetics, US Inc. are noteworthy for their contributions in facilitating accessible genetic diagnostics, while Laboratory Corporation of America Holdings and MedGenome Labs Ltd. have been instrumental in bridging the gap between cutting-edge research and clinical application. In addition, established giants such as Merck KGaA, Natera, Inc., and NextGen Genetics Holdings, LLC have strategically expanded their service portfolios to include a range of sophisticated genetic testing options.

Alongside these, companies like Ovation Fertility, PacGenomics, PerkinElmer, Inc., and Progyny, Inc. have garnered significant attention for their innovations in fertility-focused genetic diagnostics. Qiagen N.V., Quest Diagnostics Incorporated, and Reproductive Genetic Innovations, LLC have further fortified the market with robust testing solutions, while SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., and The Cooper Companies Inc. lead efforts in integrating software advancements with biological testing. Not to be overlooked, Thermo Fisher Scientific Inc., Vitrolife Sweden AB, and Yikon Genomics (Shanghai) Co., Ltd. round out a competitive landscape where collaborative innovation drives both technological improvements and market penetration.

The report delves into recent significant developments in the Preimplantation Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bio-Techne Corporation, Bioarray S.L., EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, Genea Limited, GENETiKS, Illumina, Inc., Invicta Genetics, Invitae Corporation, Juno Genetics, US Inc., Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Merck KGaA, Natera, Inc., NextGen Genetics Holdings, LLC, Ovation Fertility, PacGenomics, PerkinElmer, Inc., Progyny, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, LLC, SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., The Cooper Companies Inc., Thermo Fisher Scientific Inc., Vitrolife Sweden AB, and Yikon Genomics (Shanghai) Co., Ltd.. Actionable Recommendations for Industry Leaders

For industry leaders seeking to navigate the evolving landscape of preimplantation genetic testing successfully, several actionable recommendations stand out. One key strategy is to prioritize investment in research and development. By allocating resources to advanced genomic technologies, companies can not only enhance diagnostic accuracy but also pioneer breakthrough applications that address emerging clinical needs. Embracing innovation in next-generation sequencing and complementary technologies can facilitate the creation of more robust, user-friendly testing platforms.

Moreover, fostering collaborative partnerships between diagnostic laboratories, research institutions, and clinical service providers will be crucial in accelerating product development and streamlining regulatory pathways. Industry leaders should also focus on integrating digital solutions and artificial intelligence to optimize both data management and interpretation. By doing so, the process of genomic analysis can be made more efficient, leading to faster turnaround times and more personalized patient care.

Another critical recommendation is to enhance market penetration through strategic geographic expansion. By investing in regions with high growth potential, such as emerging markets in the Asia-Pacific and the rapidly evolving sectors in Europe, Middle East, and Africa, companies can tap into an expanding customer base. Aligning product lines with local regulatory frameworks and clinical needs will further ensure that innovations are well received in diverse markets.

Finally, it is imperative to maintain stringent quality control measures and adhere to international regulatory standards. This not only instills confidence among end-users but also fosters a competitive environment based on safety, accuracy, and superior clinical outcomes. By implementing these recommendations, industry leaders can position themselves at the forefront of an increasingly competitive and technologically advanced market.

Conclusion: The Future of Preimplantation Genetic Testing

Preimplantation genetic testing is positioned at the crossroads of rapid technological evolution and pressing clinical demand. The market is thriving due to substantial advancements in genomic technology and a clearer understanding of genetic disorders that affect reproductive health. With transformative shifts in testing methodologies and an expansive segmentation framework covering various technological and application-based arenas, the market stands to benefit from both incremental and disruptive innovations.

Globally, the market is supported by vigorous regional dynamics, with significant growth observed in the Americas, Europe, Middle East & Africa, and Asia-Pacific. Each of these regions offers unique opportunities based on their regulatory frameworks, economic environments, and healthcare infrastructures. As innovative companies continue to push boundaries, the landscape has become increasingly competitive, encouraging continuous improvement and cross-sector collaboration.

Ultimately, the future of preimplantation genetic testing is one marked by increased accuracy, efficiency, and accessibility. The cumulative effect of technological advancements, broader market segmentation, and proactive regional expansion strategies promises to redefine reproductive health care. Stakeholders who embrace these trends and invest in future-focused strategies are likely to reap substantial long-term benefits, driving both improved patient outcomes and sustainable market growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Improving healthcare infrastructure and easier access to genetic testing facilities worldwide
      • 5.1.1.2. Growing demand for in-vitro fertilization (IVF) procedures requiring preimplantation genetic testing
      • 5.1.1.3. Increasing awareness about genetic disorders and their prevention among prospective parents
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of preimplantation genetic testing procedures limiting widespread accessibility and adoption
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements enhancing accuracy and speed in preimplantation genetic testing
      • 5.1.3.2. Collaborations with IVF clinics to offer bundled preimplantation genetic testing services
    • 5.1.4. Challenges
      • 5.1.4.1. Compliance with different regional regulations and ethical standards
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Testing Type: Increasing need for PGT-M to prevent transmitting hereditary conditions
    • 5.2.2. End User: Growing utilization of preimplantation genetic testing in fertility clinics to enhance the success rates of in vitro fertilization
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Preimplantation Genetic Testing Market, by Testing Type

  • 6.1. Introduction
  • 6.2. PGT-A (Aneuploidy)
  • 6.3. PGT-M (Monogenic Disorders)
  • 6.4. PGT-SR (Structural Rearrangements)

7. Preimplantation Genetic Testing Market, by Test Type

  • 7.1. Introduction
  • 7.2. Preimplantation Genetic Diagnosis
  • 7.3. Preimplantation Genetic Screening

8. Preimplantation Genetic Testing Market, by Technology Type

  • 8.1. Introduction
  • 8.2. Comparative Genomic Hybridization
  • 8.3. Fluorescent In-Situ Hybridization
  • 8.4. Next-Generation Sequencing
  • 8.5. PCR-Based Testing
  • 8.6. Single-Nucleotide Polymorphism

9. Preimplantation Genetic Testing Market, by Offering

  • 9.1. Introduction
  • 9.2. Instruments
  • 9.3. Reagents & Consumables
  • 9.4. Software

10. Preimplantation Genetic Testing Market, by End User

  • 10.1. Introduction
  • 10.2. Diagnostic Laboratories
  • 10.3. Fertility Clinics
  • 10.4. Hospitals
  • 10.5. Research Institutes

11. Americas Preimplantation Genetic Testing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Preimplantation Genetic Testing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Preimplantation Genetic Testing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Successful PGT-HLA procedure at Jindal IVF offers hope for families facing genetic challenges
    • 14.3.2. Strategic GenEmbryomics and Progenesis partnership pioneers IVF testing with groundbreaking genetic innovations
    • 14.3.3. Natera Inc. to acquire prenatal and carrier screening assets from Invitae, to enhance patient services and market position
    • 14.3.4. Thermo Fisher Scientific launches advanced sequencing tools for preimplantation genetic testing, enhancing fertility research and reproductive health outcomes
    • 14.3.5. Medicover Genetics and Fimlab Laboratories Announce Partnership to Provide Genetic Testing Services in Finland
    • 14.3.6. U.S. Fertility and Ovation Combine to Create IVF Services Powerhouse, Increasing Access to Fertility Services
    • 14.3.7. Eurofins Genoma Announces Launch of niPGT-A, a Non-Invasive, Embryo Biopsy Free, Preimplantation Genetic Aneuploidy Screening
    • 14.3.8. GenEmbryomics Introduces the Most Complete IVF Genetic Test Ever Made Available
    • 14.3.9. Singaporeans Undergoing IVF to Get New Funding For Some Types of Preimplantation Genetic Testing
    • 14.3.10. Australia's Fertilis Raised USD 2 Million to Automate IVF Embryo Culturing
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. Bio-Techne Corporation
  • 4. Bioarray S.L.
  • 5. EUROPE IVF International s.r.o.
  • 6. F. Hoffmann-La Roche AG
  • 7. Genea Limited
  • 8. GENETiKS
  • 9. Illumina, Inc.
  • 10. Invicta Genetics
  • 11. Invitae Corporation
  • 12. Juno Genetics, US Inc.
  • 13. Laboratory Corporation of America Holdings
  • 14. MedGenome Labs Ltd.
  • 15. Merck KGaA
  • 16. Natera, Inc.
  • 17. NextGen Genetics Holdings, LLC
  • 18. Ovation Fertility
  • 19. PacGenomics
  • 20. PerkinElmer, Inc.
  • 21. Progyny, Inc.
  • 22. Qiagen N.V.
  • 23. Quest Diagnostics Incorporated
  • 24. Reproductive Genetic Innovations, LLC
  • 25. SEQUENCE46, LLC
  • 26. Sysmex Corporation
  • 27. Takara Bio Inc.
  • 28. The Cooper Companies Inc.
  • 29. Thermo Fisher Scientific Inc.
  • 30. Vitrolife Sweden AB
  • 31. Yikon Genomics (Shanghai) Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. PREIMPLANTATION GENETIC TESTING MARKET MULTI-CURRENCY
  • FIGURE 2. PREIMPLANTATION GENETIC TESTING MARKET MULTI-LANGUAGE
  • FIGURE 3. PREIMPLANTATION GENETIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 4. PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PREIMPLANTATION GENETIC TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 239. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024